Ozempic (Semaglutide)
in Thailand
A practical guide to semaglutide, medical review, treatment suitability, common side effects and the next steps for adults considering treatment support in Thailand.
Ozempic is a prescription medicine. Treatment is not guaranteed and suitability must be assessed by a licensed physician.
What is Ozempic?
Ozempic is a brand of semaglutide, a prescription GLP-1 receptor agonist used with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
Semaglutide can also affect appetite and body weight. However, Ozempic and Wegovy are different branded products with different approved uses and dose schedules. Ozempic should not be presented as interchangeable with Wegovy.
What ThailandSlim does
- Provides educational treatment information
- Routes new patients to medical consultation
- Offers a review path for previous users
- Supports physician-led treatment decisions
How semaglutide works
Semaglutide acts on the GLP-1 receptor, imitating some effects of a naturally occurring gut hormone involved in glucose regulation, appetite and digestion.
Glucose-dependent insulin
It can increase insulin release when blood glucose is elevated and help improve glycaemic control.
Appetite and fullness
It may reduce appetite and increase feelings of fullness in some patients.
Gastric emptying
It can slow stomach emptying, particularly after treatment begins, which may contribute to fullness and gastrointestinal effects.
Ozempic dosage chart
The schedule below summarises commonly used Ozempic dose escalation. It is not a personal dosing plan. Local product information, the available pen strength and the prescribing physician’s instructions always take priority.
Who may be considered?
Ozempic is primarily used for adults with type 2 diabetes. A physician may review diagnosis, HbA1c, other diabetes medicines, kidney function, gastrointestinal history, treatment goals and potential risks.
New to semaglutide
Begin with a full consultation so the medical team can assess your health history, current treatment and goals.
Already using Ozempic
Provide the exact pen, current dose, last injection date, treatment response and side-effect history.
Considering weight management
A physician should explain whether Ozempic, Wegovy or another treatment better matches the approved clinical purpose and your health profile.
What the doctor may ask
- Type 2 diabetes history and recent glucose control
- Current medicines, including insulin or sulfonylureas
- Previous semaglutide or other GLP-1 treatment
- Kidney, pancreas, gallbladder or gastrointestinal history
- Diabetic eye disease or changes in vision
- Pregnancy, breastfeeding or plans for pregnancy
- Previous side effects and treatment response
Common and serious side effects
| Common effects | Contact a clinician | Seek urgent care |
|---|---|---|
| Nausea, diarrhoea, vomiting, abdominal discomfort, constipation, indigestion or reduced appetite. | Persistent vomiting, inability to drink, signs of dehydration, worsening vision, severe constipation or symptoms that do not improve. | Severe or persistent abdominal pain, signs of a serious allergic reaction, fainting, chest pain or another urgent medical concern. |
Ozempic vs Wegovy
Both products contain semaglutide, but they are not the same treatment programme. They differ in approved use, dose escalation and maximum maintenance dose.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| General approved purpose | Type 2 diabetes treatment | Chronic weight management for eligible patients |
| Typical starting dose | 0.25 mg once weekly | 0.25 mg once weekly |
| Typical maintenance range | 0.5 mg or 1 mg; 2 mg in some markets | Usually escalated toward a higher weight-management maintenance dose according to product information |
| Interchangeable? | No. Do not switch products or copy one product’s dosing schedule to the other without medical guidance. | |
How the ThailandSlim process works
Choose the correct path
New patients start with consultation. Previous users start with treatment review.
Submit information
Provide your health history, diabetes medicines, treatment history and goals.
Medical review
A physician reviews suitability and may request laboratory results or additional information.
Receive the next step
If treatment may be appropriate, the team explains the plan, monitoring and follow-up requirements.
Treatment works best with follow-up
Medication does not replace nutrition, movement, hydration, sleep or ongoing diabetes care.
- Use the same scheduled day each week unless instructed otherwise
- Follow storage and pen instructions exactly
- Stay hydrated, especially if nausea or diarrhoea occurs
- Monitor glucose as directed
- Attend follow-up and report side effects
Compare your options
Ready to take the next step?
Choose the correct path based on whether you are new to treatment or already using Ozempic or another weight-management medicine.
Frequently asked questions
Is Ozempic the same as semaglutide?
Ozempic is a brand name for a semaglutide injection. Other semaglutide products can have different approved uses, strengths and dosing schedules.
Is Ozempic approved specifically for weight loss?
Ozempic is primarily authorised for type 2 diabetes. Wegovy is the semaglutide brand developed and authorised for chronic weight management in eligible patients. Local approvals and availability should be confirmed.
Can I start at 1 mg or 2 mg?
Do not select a starting dose yourself. Ozempic is normally started at a lower dose and increased gradually to improve tolerability.
Can I switch directly from Wegovy or Mounjaro?
Do not switch products or doses without medical review. The active ingredient, mechanism, dose schedule and timing of the last injection all matter.
What if I miss a dose?
Follow the instructions supplied with the exact Ozempic product and contact a clinician or pharmacist when uncertain. Do not take extra medicine to compensate without guidance.
Are results guaranteed?
No. Blood glucose, appetite, weight and side-effect responses vary between individuals.
Information basis: Current regulatory product information from the European Medicines Agency and the applicable local prescribing information should be consulted before treatment. Product approvals, pen strengths and maximum doses can vary by country.